Floatz logo

ptk787

Refractory Malignancy

SCRI Development Innovations, LLCPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

181 Active assets in the Refractory Malignancy cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

ptk787 is also rated in:

neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
rectal neoplasmDormant
B
Indicative ·
60 / 100
View asset →
colonic neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →